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Abstract: mRNA 3’-end processing involves the addition of a poly(A) tail based on the recognition of the poly(A) signal and subsequent
cleavage of the mRNA at the poly(A) site. Alternative polyadenylation (APA) is emerging as a novel mechanism of gene expression
regulation in normal and in disease states. APA results from the recognition of less canonical proximal or distal poly(A) signals leading
to changes in the 3’ untranslated region (UTR) lengths and even in some cases changes in the coding sequence of the distal part of
the transcript. Consequently, RNA-binding proteins and/or microRNAs may differentially bind to shorter or longer isoforms. These
changes may eventually alter the stability, localization, and/or translational efficiency of the mRNAs. Overall, the 3’ UTRs are gaining
more attention as they possess a significant posttranscriptional regulation potential guided by APA, microRNAs, and RNA-binding
proteins. Here we provide an overview of the recent developments in the APA field in connection with cancer as a potential oncogene
activator and/or tumor suppressor silencing mechanism. A better understanding of the extent and significance of APA deregulation will
pave the way to possible new developments to utilize the APA machinery and its downstream effects in cancer cells for diagnostic and
therapeutic applications.
Key words: Alternative polyadenylation, mRNA, untranslated region, cancer, cleavage stimulatory factor, cleavage and polyadenylation
stimulatory factor

1. Introduction
Polyadenylation, a cotranscriptional process, was first
identified in the nuclear extracts of calf thymus as early
as the 1960s (Edmonds and Abrams, 1960). All eukaryotic
pre-mRNAs undergo polyadenylation, i.e. cleavage and
polyadenylation at the 3’ untranslated region (UTR),
except replication-dependent histone transcripts that are
processed by small nuclear ribonucleoproteins (Marzluff
et al., 2008).
In essence, a poly(A) tail is added to the 3’ UTR of
newly synthesized pre-mRNAs by the poly(A) polymerase,
followed by the recognition of the poly(A) signal and
endonucleolytic cleavage of the pre-mRNA at the poly(A)
site. Conserved upstream elements (U-rich elements,
UGUA elements) found at ~10–35 nucleotides upstream
of the poly(A) site aid the poly(A) signal (AAUAAA,
AUUAAA, and other variants) selection. Downstream
elements are the U-rich and GU-rich elements (Tian
and Graber, 2012). Polyadenylation prolongs mRNA
lifespan by protecting the 3’ downstream sequences
against exosome nucleases and plays roles in export to
cytosol, localization, stability, and translation (reviewed
by Guhaniyogi and Brewer, 2001; Lutz and Moreira,
2011). Given these functional roles of polyadenylation,
* Correspondence: erson@metu.edu.tr

variations in 3’ UTR processing mechanisms such as
alternative polyadenylation (APA) are to be expected to
affect the length/reading frame, stability, localization, and
translational efficiency (Lutz and Moreira, 2011; Elkon
et al., 2013). As polyadenylation is a cotranscriptional
process, it is also plausible to consider mRNA processing
steps to affect and/or regulate polyadenylation efficiency
and specificity (Proudfoot et al., 2002).
While the extent of APA is better understood today
with improvements in high-throughput sequencing
techniques, isolated cases of APA events were reported
much earlier, in the 1980s, for the IgM (immunoglobulin
M) and DHFR (dihydrofolate reductase) genes. Intronic
APA-generated isoforms of IgM were found to encode
two distinct proteins, secreted if the proximal APA site is
used or membrane-bound if the distal site is used (Alt et
al., 1980; Early et al., 1980; Rogers et al., 1980). DHFR, on
the other hand, has four isoforms with identical reading
frames but different 3’ UTR lengths (Setzer et al., 1980).
Since then, an improved understanding of the extent of
APA events in the genome suggests an impressive 70% of
known human genes to harbor multiple poly(A) sites in
their 3’ UTRs and high conservation of APA sites among
different species (Derti et al., 2012).

529

AĞUŞ and ERSON BENSAN / Turk J Biol
While the role of APA-based isoform generation has
been linked to normal processes, findings suggest APA
to be a novel and important deregulated mechanism
in diseases, especially cancer. In this review, we aim to
provide an overview of current data on APA and known
consequences of altered 3’ UTR lengths during the
complex events of tumorigenesis.
2. Polyadenylation mechanisms
To better understand the complexity of polyadenylation
and APA, proteins known to be involved in these processes
will be described with potential roles in cancer development
when their expressions are altered. Pre-mRNA 3’ UTRs have
long been known to be important for the nuclear export,
stability, and translational efficiency of mRNAs. With
recent developments, 3’ UTR-based posttranscriptional
processing mechanisms are gaining attention as important
modulators of gene expression. APA is an example of how
much complexity exists for posttranscriptional regulation,
specifically for 3’-end processing. So far, we know that the
3’-end processing machinery is quite complex, comprising
approximately 85 proteins, some of which are known to be
core elements whereas others may mediate crosstalk with
other processes including splicing (Shi et al., 2009). Not
surprisingly, the polyadenylation complex is quite large
and has a comparable size similar to that of bacterial large
ribosomal subunits (1.5 MDa) (Radermacher et al., 1987).
The polyadenylation complex consists of cleavage
and polyadenylation stimulatory factor (CPSF), cleavage
stimulatory factor (CSTF), cleavage factor Im (CFIm),
and cleavage factor IIm (CFIIm), along with the scaffold
protein symplekin and poly(A) polymerase (PAP). Known
key APA machinery proteins are summarized in Figure. 1.
The most conserved motif among eukaryotic mRNA
polyadenylation signals is AAUAAA, specifically
recognized by the multisubunit CPSF complex and
therefore providing sequence specificity in the pre-mRNA
cleavage site and polyadenylation. CPSF consists of hFip1,
WDR33 (WD repeat domain 33), CPSF30, CPSF73,
CPSF100, and CPSF160 subunits (Millevoi and Wagner,
2010). CPSF subunits CPSF30 and WDR33 directly contact
the AAUAAA region (Chan et al., 2014; Schönemann et
al., 2014) and the CPSF73 subunit is the endonuclease
positioned on the cleavage site (Mandel et al., 2006). PAP
associates with cleavage and polyadenylation specificity
factors CPSF160 and CPSF73 subunits and also with the
targeted pre-mRNA (Laishram and Anderson, 2010).
Evidence suggests the CPSF complex to also crosstalk with
transcriptional initiation and elongation steps through
interactions with transcription factor IID (TFIID), RNA
polymerase II (Dantonel et al., 1997; Nag et al., 2007;
Glover-Cutter et al., 2008), and splicing machinery
through spliceosomal factor TRAP150 (Kwon et al., 2014).
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Another complex, CSTF, recognizes U- and GU-rich
sequences and is composed of 3 subunits: CSTF1 (50
kDa), CSTF2 (64 kDa), and CSTF3 (77 kDa) (Shi et al.,
2009; Millevoi and Wagner, 2010). CSTF2 (also known as
CSTF64) has 557 amino acid residues, including an RNAbinding domain and a pentapeptide repeat region that
appears to be necessary for cleavage and polyadenylation
(Takagaki et al., 1992; Takagaki and Manley, 1997).
While CSTF2 interacts directly with the GU-rich region
downstream of the cleavage site (Takagaki and Manley,
2000; Yao et al., 2012), CSTF1 and CSTF3 subunits interact
with the C-terminal domain of RNA polymerase II, possibly
to facilitate activation of 3’ UTR processing proteins
(Cevher et al., 2010). Among CSTF subunits, CSTF64
has gained special attention due to its potential role in the
selection of alternate (proximal or distal) poly(A) signals.
A transcriptome study reported the depletion of CSTF64
(and its paralogue, CSTF64τ) to result in increased usage
of distal poly(A) sites in HeLa cells, indicating that, when
present, these factors increase the selection of proximal
sites, leading to shorter isoform generation (Yao et al.,
2012). Interestingly, CSTF64 was also proposed to play
a key role in modulating the cell cycle in normal and in
embryonic stem cells while also simultaneously controlling
histone mRNA 3’-end processing (Romeo et al., 2014).
The UGUA upstream element provides binding sites
for the CFI complex (CFIm25, CFIm59, and CFIm68),
which facilitates the binding of CPSF (Fip1 subunit) to the
UTR (Coseno et al., 2008; Yang et al., 2010). The tetrameric
complex consists of the two 25-kDa subunits partnering
with either the 59- or 68-kDa subunits (Martin et al., 2010).
Structural studies revealed that the two CFIm complexes
bind to two UGUA elements in an antiparallel manner
and provide the looping of RNA (Li et al., 2011; Yang et
al., 2011). It appears that the CFI complex is important for
poly(A) site selection as, for several genes, the sites shifted
to distal ones when CFIm25 (also known as NUDT21)
levels were reduced by siRNA in HeLa cells (Kubo et al.,
2006; Fukumitsu et al., 2012; Gruber et al., 2012; Martin
et al., 2012). In addition, loss of function of CFIm68 and
CFIm25 but not of CFIm59 leads to a transcriptome-wide
increase in the use of proximal polyadenylation sites in
HEK293 cells (Gruber et al., 2012; Martin et al., 2012).
CFI proteins are also likely to function in splicing but have
different roles as CFIm59 but not CFIm68 was found to
interact with splicing factor U2AF65 (Millevoi et al., 2006),
whereas CFIm68 interacts with SR proteins (Dettwiler et
al., 2004). CFIm68 can also shuttle between the nucleus
and cytoplasm during the cell cycle (Cardinale et al., 2007)
and possibly participates in mRNA export (Ruepp et al.,
2009).
While the detailed mechanisms needs to be further
studied, the CFIIm complex seems to be important for
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Figure 1. 3’ UTR cleavage and polyadenylation machinery. CPSF complex consists of Fip1, WDR33, CPSF30, CPSF73, CPSF100, and
CPSF160. Binding of CFI on UGUA upstream sequences facilitates assembly of CPSF complex on the cleavage site. Two CFIm complexes
bind to two UGUA elements in an antiparallel manner and provide the looping of RNA. CPSF subunits CPSF30 and WDR33 directly
contact the AAUAAA region and CPSF160 and CPSF73 interact with poly(A) polymerase (PAP) (not shown). Symplekin interacts with
both CPSF73 and CSTF64 and provides a connection between polyadenylation factors. When recognized, the polyadenylation site
(p(A) site) is cleaved by the endonucleolytic activity of CPSF73. CSTF77 acts as a bridge between CSTF64 and CSTF50. The interaction
between CSTF50-CSTF77 and the C-terminal domain of RNA polymerase II probably facilitates activation of RNA polymerase II
mediated 3’-end processing and assembly of other complexes. After cleavage, PAP starts to polymerize the adenine tail.

the efficient degradation of the 3’ product of poly(A)
site cleavage and transcriptional termination (West
and Proudfoot, 2008). Symplekin, as an essential
polyadenylation factor, was shown to bind to CPSF73 and
CSTF64 at the early steps of the polyadenylation process,
possibly to function as a scaffold protein (Barnard et al.,
2004; Ruepp et al., 2010).
3. APA and cancer
Following the pivotal work of Sandberg et al. (2008),
describing the increase in expression of shortened mRNA
3’ UTR isoforms after activation of primary murine CD4+

T lymphocytes, various other studies demonstrated APA
changes in normal and/or cancer cells by delineating
functional APA sites using EST databases, microarray data,
and modified RNA-seq techniques. These studies provided
a link between proliferation/APA and cancer, as well as
between development and tissue-specific polyadenylation
patterns. For example, transcripts in the nervous system
and brain and during mouse embryonic development are
very specifically characterized by distal poly(A) site usage,
whereas induced pluripotent stem cells (iPSCs) from
differentiated cells are accompanied by global 3’ UTR
shortening (Ji et al., 2009).

531

AĞUŞ and ERSON BENSAN / Turk J Biol
Given the specific APA patterns in normal cells,
defective global alternative polyadenylation was reported
for numerous cancers including colorectal carcinomas,
esophageal cancers, breast cancers, and small intestinal
neuroendocrine tumors, suggesting APA as a new target
for both diagnosis and treatment options (Mayr and Bartel,
2009; Fu et al., 2011; Morris et al., 2012; Rehfeld et al., 2014;
Sun et al., 2014). One of the recent findings on APA and
tumorigenesis comes from glioblastomas. Approximately
1500 genes with shortened 3’ UTRs were discovered after
CFIm25 knockdown followed by a marked increase in
the expression of several known oncogenes, including
CYCLIN D1. Furthermore, a subset of APA-deregulated
genes was discovered in the low-CFIm25-expressing
glioblastomas (Masamha et al., 2014). A functional link
between APA and glioblastoma was also reported based
on downregulation of CFIm25 expression in glioblastoma
cells and enhanced tumorigenic properties.
In addition to the high-throughput approaches
demonstrating a global bias towards generation of short
or long isoforms, individual mRNA-APA studies have
also been imperative to improve the understanding of
the significance of APA in cancers. For example, ECE1 (endothelin-converting enzyme-1) is responsible
for producing active endothelin-1, an overexpressed
mitogenic peptide in cancers especially associated with
poor prognosis and aiding the acquisition of androgen
independence in prostate cancers. APA results in the
production of ECE-1 transcripts with shorter 3’ UTRs,
which promote elevated protein expression as a means
to activate oncogenes (Whyteside et al., 2014). In line
with earlier findings, our group reported the role of
hormones in APA, and specifically estradiol, in breast
cancers to cause 3’ UTR shortening of CDC6, possibly
through E2Fs, transcription factors involved in cell cycle
regulation. CDC6 itself is also a major regulator of the S
phase and 3’ UTR shortening of CDC6 contributes to the
consequent proliferation of ER(+) breast cancer cells in
response to estradiol (Akman et al., 2012). In connection,
earlier, a role for E2F was proposed for the transcriptional
regulation of some APA proteins, providing a mechanistic
link between APA and proliferation (Elkon et al., 2012).
Another example important for cellular transformation
processes is VEGFR2 (vascular endothelial growth factor
receptor 2), controlled by intronic APA. The VEGFR2
gene can transcribe a functional receptor using the distal
poly(A) signal or a soluble decoy protein, if the proximal
intronic poly(A) signal is preferred in connection with the
splicing machinery (Vorlová et al., 2011). Furthermore,
as VEGFR2 mediates important angiogenic signaling,
inhibitory antisense oligonucleotides to the nearest
upstream splicing site of the intronic poly(A) signal results
in increased expression of the soluble form of VEGFR2
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protein and blockade of angiogenic signals, which may
indicate the potential therapeutic implication of APA
(Vorlová et al., 2011).
Taken together, it is interesting to observe how APA
may provide an additional level of gene expression
control. However, our understanding of how and why a
specific polyadenylation site is selected over another is far
from complete. Transcriptional rate, levels of key poly(A)
proteins, and/or alternate targeting of isoforms by either
RNA-binding proteins (RBPs) and/or microRNAs are
found to be contributing factors to APA. In essence, APA
(and its regulation) can be affected by many internal and
external factors such as proliferation signals, hormones,
developmental stages, epigenetic modifications, and even
UV-induced DNA damage (Kleiman and Manley, 2001).
Potential internal and external regulatory signals for
APA are shown in Figure. 2. Hence, we would like to a
give an overview of reported APA events that are linked
to the above cellular events given their significance in
tumorigenesis.
4. Transcriptional kinetics
Several lines of evidence have linked APA to transcriptional
activity (initiation or elongation). In mice and humans,
short 3’ UTR isoforms are more abundant for highly
expressed genes, whereas long 3’ UTR isoforms are more
abundant for lower expression genes, possibly due to RNA
polymerase II activity and/or chromatin structure (Ji et
al., 2011). Since short 3’ UTRs are generally more stable
due to avoidance of negative regulatory elements in the 3’
UTRs (Mayr and Bartel, 2009), more production of short
3’ UTR isoforms would make the overall expression level
of proteins higher, consistent with oncogene expression
cases in cancer cells. Given that highly proliferating cancer
cells require increased protein synthesis, transcriptional
kinetics and APA connections become interesting for
further examination.
In addition to transcription initiation, transcriptional
elongation may also be another factor to determine
poly(A) signal selection. Supporting evidence comes
from Drosophila mutants with a 50% decrease in RNA
polymerase II elongation rates. In mutants, proximal
poly(A) site selection was higher compared to wild-type
animals (Pinto et al., 2011). Another interesting example is
from yeast. In normally growing yeast cells, the proximal
poly(A) site is preferred for the RPB2 (RNA polymerase II
subunit B2) gene. However, after UV damage, transcription
of RPB2 is initially inhibited. As transcription recovers, the
distal poly(A) site is preferentially used instead, producing
more of a longer form of RPB2 mRNA (Yu and Volkert,
2013).
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Figure 2. Potential regulatory signals for APA. APA is potentially affected by many factors including proliferation and activation
signals, transcriptional activity, RNA polymerase elongation rate, splicing, epigenetic marks, APA protein levels, RNA-binding proteins,
microRNAs, and DNA damage. These APA-inducing mechanisms are likely to crosstalk with each other. Following the APA decision,
the short or long isoform of a transcript is generated. These isoforms may have the same coding sequence as different 3’ UTRs or
different reading frames based on the position of the poly(A) site.

5. Splicing
U1 is a ubiquitously expressed small nuclear
ribonucleoprotein and is a major part of the spliceosome
complex. Interestingly, morpholino oligonucleotideinduced knockdown of U1 in HeLa cells results in
generation of premature cleavage and polyadenylation
in numerous pre-mRNAs at cryptic polyadenylation
signals in introns (Kaida et al., 2010). In connection to
its role in polyadenylation, U1 was later proposed as a
determinant of mRNA length and a regulator of different
isoform expression patterns (Berg et al., 2012). Given
the polyadenylation process being highly dependent on
transcriptional activity, it is not surprising to observe
potential interactions between the splicing machinery and
APA. It is clear that we will see more examples of how APA
and splicing may coregulate generation of specific UTR
isoforms.
6. Epigenetic marks
Transcriptional activity is also known to affect epigenetic
features; therefore, regulation of APA by transcriptional
activity also correlates with differences in nucleosome
positioning and histone methylation patterns around
alternative poly(A) sites. Indeed, preferred poly(A) sites

are strongly depleted of nucleosomes, whereas neighboring
regions can be enriched for nucleosomes (Spies et al., 2009).
Given the high conservation of APA signals among species
and epigenetic alterations in cancer cells, further studies
on mammalian systems will be of interest to investigate the
depth of the connections among transcriptional kinetics,
associated epigenetic marks, and APA.
7. APA protein levels
Another potential contributor to APA usage is the
changes in APA protein levels in cells. Initial evidence
supporting the role of key proteins in APA comes from
B-cell differentiation where upregulation of CSTF64 leads
to a switch from distal to proximal poly(A) site selection
for the IgM heavy chain, leading to the conversion of
IgM heavy chain from membrane-bound to secreted
form, which is required for B-cell activation (Takagaki
and Manley, 1998). CSTF64 was also shown to be
upregulated upon T-cell stimulation, leading to shorter
isoform generation of the transcription factor, NFATC, in
effector cells, whereas both short and long isoforms are
synthesized in unstimulated cells (Chuvpilo et al., 1999).
Lipopolysaccharide stimulation has also been reported to
increase CSTF64 expression in macrophages to promote
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alternative polyadenylation of several mRNAs (Shell et al.,
2005). In addition to proliferative/activatory signals, cell
death decisions may also have effects on APA. For example,
CPSF73 is translocated from the nucleus to cytosol by
CSR1 (cell stress response 1). CSR1 is overexpressed
under oxidative stress conditions and induces apoptosis.
Consequently, CPSF73 translocation to the cytosol results
in a significant inhibition of overall polyadenylation
activity in prostate cancers (Zhu et al., 2008).
8. RNA-binding proteins and microRNAs
Perhaps also in connection with some of the above
mechanisms, growing lines of evidence have shown that
RBPs play roles in the regulation of APA by either directing
poly(A) site selection or being part of the APA machinery.
RBPs may also regulate translation by interacting
exclusively with specific cis elements in the 3’ UTRs. Some
of these cis regulatory elements are A+U-rich elements,
CU-rich elements, stem-loop destabilizing elements
(reviewed by Knapinska et al., 2005), polyadenylation
inhibition elements (Clerte and Hall, 2004), and GU-rich
elements (Vlasova et al., 2008). While the roles of RBPs
binding to these cis elements are just beginning to be
understood in cancer cells, few of these proteins have been
implicated in APA as well. For example, HuR is a member
of the human embryonic lethal abnormal vision (ELAV)
family of proteins, originally identified in Drosophila, and
is ubiquitously expressed. HuR has been shown to regulate
many cancer-related mRNAs such as tumor suppressors
(TP53, p21, and p27), oncogenes (c-fos, c-Myc), cyclins (A,
B1, D1), various growth factors (VEGF, TGFβ, and TNFα),
and apoptosis-related factors (BCL-2, MCL-1). HuR has
also been implicated in cancer-related phenomena such
as hypoxia or inflammatory signals (reviewed by Wurth
and Gebauer, 2015). Interestingly, HuR overexpression in
HeLa cells blocks polyadenylation at poly(A) signals only
if they contain U-rich sequences, possibly by blocking
the physical interaction between CSTF64 and the mRNA
(Zhu et al., 2007). Therefore, alterations in HuR levels
may have profound secondary effects on multiple target
mRNAs both in terms of its role in stabilizing mRNAs and
binding to potential poly(A) sites in cancer cells. Indeed,
cytoplasmic localization of HuR has shown to be a poor
prognostic factor in several cancer types including breast,
lung, colon, esophageal squamous cell carcinoma, and
ovarian carcinomas (Wurth and Gebauer, 2015).
PABPN1 (nuclear poly(A) binding protein) appears
to be contributing to the regulation of APA by inhibiting
proximal polyadenylation. PABPN1 directly interacts
with noncanonical and weak proximal poly(A) signals
and possibly competes with the APA machinery as loss
of PABPN1 leads to a genome-wide 3’ UTR shortening
pattern (Elkon et al., 2012). Lower expression of PABPN1
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is also linked to poor prognosis in nonsmall-cell lung
cancers (Ichinose et al., 2014). Another RBP, which
regulates mRNA translation, is CPEB1 (cytoplasmic
polyadenylation binding protein 1), which interacts with
CPSF and splicing factors in the nucleus. CPEB1 mediates
shortening of hundreds of mRNA 3’ UTRs. In addition
to 3’ UTR shortening due to alternative polyadenylation,
CPEB1 mRNA interaction has also been linked to
alternative splicing (Bava et al., 2013).
Interestingly, two cold-induced RBPs, CIRBP and
RBM3, have been found to repress proximal poly(A) site
usage under cold shock conditions, leading to longer 3’
UTR isoforms (Liu et al., 2013). Further investigations
revealed that many of these APA events had circadian
oscillations depending on the ambient temperature. It
will be of interest to investigate the mechanism of this
connection.
In addition to RBPs, microRNAs are small, endogenous,
noncoding RNAs that also target 3’ UTRs. By binding to
target mRNAs, microRNAs can degrade, destabilize, delay,
or suppress translation of mRNAs (Akman and ErsonBensan, 2014). While the role of deregulated microRNAs
has been well established in cancers, an interesting
metaanalysis of 3’ UTR lengths and microRNA expression
profiles suggested upregulated microRNA expression
profiles to be highly correlated with a shift towards shorter
isoforms in breast cancer cells, possibly due to increased
degradation of the longer isoforms (Liaw et al., 2013).
Indeed, when microRNA prediction algorithms are used,
there is generally a clear preference for microRNA binding
sites for the longer isoforms simply due to the availability
of more binding sites. To support this observation, earlier
we used several microRNA binding predictions for the
short and long CDC6 isoforms and detected a common
microRNA binding profile for the longer isoform. Indeed,
western blot analysis and luciferase reporter assays
confirmed increased CDC6 levels upon 3’ UTR shortening
and higher translation of the shorter isoform (Akman
and Erson-Bensan, 2014). Cyclooxygenase 2 (COX-2),
overexpressed in some cancers, has also been shown to be
regulated by microRNAs (miR-146) in connection with
APA (Cornett and Lutz, 2014). Cellular inflammatory
responses, APA, and microRNA connection may be
functionally interesting to examine in cancer cells as a
potential way to activate oncogenes.
From the perspective of normal cellular events and
cancer, it appears that APA is not regulated by a single
mechanism and that different physiological states and/or
signals can potentially be functionally important for APAbased UTR isoform generation. Considering the hallmarks
of cancer, increased proliferation rates and activated
signaling cascades, APA may emerge as an additional
mechanism to explain certain oncogene activation and/
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or tumor suppressor inactivation cases where no other
explanation exists. Exciting developments clearly show the
significance of UTR shortening and lengthening events in
cancers and it is interesting to further evaluate microRNA
deregulation in connection with APA. It should also be
emphasized that one needs to be careful and take into
consideration how RBPs may also bind to short or long
isoforms in addition to microRNAs as RBPs may have
stabilizing roles. Moreover, 3’ UTR-isoform choice and
influence on the stability and translational efficiency may
not always correlate, as was shown in mouse fibroblasts
(Spies et al., 2013).
On the other hand, several examples of mutated
poly(A) sites were found to be associated with other
diseases such as neonatal diabetes, type I and II diabetes,
preeclampsia, fragile X-associated premature ovarian
insufficiency, ectopic Cushing syndrome, and myotonic
dystrophy type I (Rehfeld et al., 2013; Batra et al. 2014).

For example, an A-to-G conversion was shown to drive
the polyadenylation complex to a distal poly(A) site,
which resulted in destabilization of FOX3P mRNA and
decreased protein levels in IPEX (immune dysfunction,
polyendocrinopathy, enteropathy, X-linked) patients (Di
Giammartino et al., 2011). Aberrant spermatogenesis was
also reported when testis-specific CSTF64 was disrupted
(Dass et al., 2007).
In summary, the extent and functionality of APA
deregulation in disease states including cancer must be
established so as to pave the way to new developments
to utilize APA machinery and its downstream effects for
diagnostic and therapeutic applications.
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